

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Lead Product(s) : Bromocriptine
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Mie University | Osaka University | Tokushima University | Tokyo Metropolitan Geriatric Medical Center | Asakayama Hospital | Kawasaki Medical School Hospital | Nagoya City University Hospital | Time Therapeutics, Inc. | Towa Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease
Details : Bromocriptine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 02, 2020
Lead Product(s) : Bromocriptine
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Mie University | Osaka University | Tokushima University | Tokyo Metropolitan Geriatric Medical Center | Asakayama Hospital | Kawasaki Medical School Hospital | Nagoya City University Hospital | Time Therapeutics, Inc. | Towa Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Bromocriptine
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Satisfaction of Patients With the Chosen Method of Inhibition of Lactation
Details : Bromocriptine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 31, 2019
Lead Product(s) : Bromocriptine
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Bromocriptine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bromocriptine for Patients with Schizophrenia and Prediabetes
Details : Bromocriptine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 02, 2018
Lead Product(s) : Bromocriptine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Bromocriptine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Bromocriptine on Insulin Resistance in Polycystic Ovarian Syndrome - A Pilot Study
Details : Bromocriptine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Polycystic Ovary Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 08, 2014
Lead Product(s) : Bromocriptine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
